Pulmatrix (Pulmatrix) Cash And Cash Equivalents

: $19.17 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Pulmatrix's quarterly cash and cash equivalents declined from Jun. 2023 ($25.79 Mil) to Sep. 2023 ($21.34 Mil) but then stayed the same from Sep. 2023 ($21.34 Mil) to Dec. 2023 ($19.17 Mil).

Pulmatrix's annual cash and cash equivalents declined from Dec. 2021 ($53.84 Mil) to Dec. 2022 ($35.63 Mil) and declined from Dec. 2022 ($35.63 Mil) to Dec. 2023 ($19.17 Mil).

Pulmatrix Cash And Cash Equivalents Historical Data

The historical data trend for Pulmatrix's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmatrix Annual Data

Trend

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

23.44

31.66

53.84

35.63

19.17

Pulmatrix Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															35.63	30.75	25.79	21.34	19.17

Pulmatrix Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Pulmatrix (NAS:PULM) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Pulmatrix Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Pulmatrix's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Pulmatrix (Pulmatrix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pulmatrix Inc (NAS:PULM) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

2PU:Germany

Address

99 Hayden Avenue, Suite 390, Lexington, MA, USA, 02421

Website

https://www.pulmatrix.com

Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.

Executives

Peter Ludlum	officer: Interim CFO	20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Margaret Wasilewski	officer: Chief Medical Officer	C/O PULMATRIX, INC., 99 HAYDEN AVENUE, SUITE 390, LEXINGTON MA 02421
Anand Varadan	director	C/O CHIASMA, INC., 60 WELLS AVENUE, NEWTON MA 02459
Todd Bazemore	director	C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Christopher Cabell	director	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Michelle Siegert	officer: Vice President, Finance	99 HAYDEN AVENUE, SUITE 390, LEXINGTON MA 02421
Richard P. Batycky	director	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Robert Nelsen	other: Former 10% owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Polaris Venture Partners Founders' Fund V, L.p.	10 percent owner	ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners Entrepreneurs' Fund V, L.p.	10 percent owner	ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners Special Founders' Fund V, L.p.	10 percent owner	ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners V, L.p.	10 percent owner	ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Management Co. V, L.l.c.	10 percent owner	ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Jonathan A Flint	10 percent owner	1000 WINTER STREET, SUITE 3350, WALTHAM MA 02451
Polaris Venture Management Co Iv Llc	10 percent owner	ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210